Literature DB >> 11432777

Correlative fine specificity of several Thomsen-Friedenreich disaccharide-binding proteins with an effect on tumor cell proliferation.

F J Irazoqui1, B Jansson, P H Lopez, G A Nores.   

Abstract

Epithelial cancer cells show increased cell surface expression of mucin antigens with aberrant O-glycosylation, notably type I core (Galbeta1-3GalNAcalpha), termed Thomsen-Friedenreich disaccharide (TFD), a chemically well-defined carbohydrate antigen with a proven link to malignancy. Several TFD-binding proteins influence the proliferation of cells to which they bind. We studied the fine specificity of TFD-binding proteins and its relationship with epithelial tumor cell proliferation. Competitive binding assays against asialoglycophorin showed that Agaricus bisporus lectin (ABL) and human anti-TFD monoclonal antibody (mAb) TF1 were inhibited only by TFD and its alpha-derivatives. Peanut agglutinin (PNA), mAb TF2, and mAb TF5 were also inhibited by other carbohydrates such as lacto-N-biose (Galbeta1-3GlcNAc), lactose, and (Mealpha or beta) Gal, indicating lower recognition of the axial C-4 hydroxyl group position of GalNAc from TFD, and the major relevance of the terminal Gal on interaction of these three TFD-binding proteins. In the direct glycolipid-binding assay, ABL bound mostly to alpha-anomeric TFD-bearing glycolipids, whereas PNA interacted mainly with beta-linked TFD. Of the three anti-TFD mAbs analyzed, all bound N5b (terminal beta-TFD), but only TF2 interacted with N6 (terminal alpha-TFD). These findings indicate that TFD-binding proteins that stimulate the proliferation of epithelial tumor cell lines recognize mainly a terminal beta-Gal region of beta-linked TFD, whereas ABL, which inhibits the proliferation of these tumor cells, binds mainly to subterminal GalNAc of alpha-anomeric TFD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432777     DOI: 10.1093/oxfordjournals.jbchem.a002959

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  5 in total

1.  Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody.

Authors:  Udo Jeschke; Uwe Karsten; Irmi Wiest; Sandra Schulze; Christina Kuhn; Klaus Friese; Hermann Walzel
Journal:  Histochem Cell Biol       Date:  2006-04-11       Impact factor: 4.304

2.  Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.

Authors:  Jamie Heimburg; Jun Yan; Susan Morey; Olga V Glinskii; Virginia H Huxley; Linda Wild; Robert Klick; Rene Roy; Vladislav V Glinsky; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 3.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

4.  Determination of multivalent protein-ligand binding kinetics by second-harmonic correlation spectroscopy.

Authors:  Krystal L Sly; John C Conboy
Journal:  Anal Chem       Date:  2014-10-29       Impact factor: 6.986

Review 5.  Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.

Authors:  Oleg Kurtenkov
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.